Hypercalcemia Management

Diagnosis and Classification

• Hypercalcemia severity is classified as mild (< 12 mg/dL), moderate (12-13.5 mg/dL), or severe (> 13.5 mg/dL) based on corrected serum calcium levels, as recommended by the American College of Chest Physicians 1
• Corrected calcium levels can be calculated using the formula: Corrected calcium = Total calcium + 0.8 × (4.0 - serum albumin) if ionized calcium is not available, by the National Institute of Diabetes and Digestive and Kidney Diseases and the American College of Physicians 2, 3
• Initial laboratory tests for hypercalcemia include corrected calcium calculation, intact parathyroid hormone (iPTH), phosphorus, magnesium, renal function tests, 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels, and urinary calcium/creatinine ratio, to differentiate PTH-dependent from PTH-independent causes, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases and the American College of Physicians 4, 2, 5, 6, 3

Treatment Strategies

• Administer IV normal saline to correct hypovolemia and promote calciuresis, addressing dehydration commonly associated with hypercalcemia and helping to lower calcium levels through dilution and increased renal excretion in patients with hypercalcemia 2
• Administer zoledronic acid 4 mg IV over at least 15 minutes to reduce the risk of renal toxicity, as recommended by the American Society of Clinical Oncology 2
• Alternative treatment: Pamidronate 90 mg IV over 2 hours can be used to manage hypercalcemia 2
• Expected response to treatment: Normalization of calcium levels in approximately 50% of patients by day 4, according to the European Society for Medical Oncology 2
• The following treatment steps are recommended:

• Denosumab is recommended for cases not responding to bisphosphonates or in patients with severe renal impairment, according to the European Society for Medical Oncology 2
• Diuretics such as furosemide should only be used after correcting hypovolemia to help increase calcium excretion, as recommended by the American College of Chest Physicians 1

Special Considerations

• Patients with CKD who are treated with vitamin D or calcium supplementation are at increased risk of developing hypercalcemia, especially those with low-turnover bone disease, and the National Kidney Foundation recommends reducing or discontinuing vitamin D supplementation and considering non-calcium-based phosphate binders 7
• Malignancy-related hypercalcemia has a poor prognosis, with a median survival of approximately 1 month in lung cancer, and hypercalcemia occurs in 10-25% of patients with lung cancer, more commonly in patients with squamous cell carcinoma, as stated by the American College of Chest Physicians 1

Monitoring and Follow-up

• Regular monitoring of serum calcium, phosphate, magnesium, and renal function is essential, as well as watching for hypocalcemia after treatment, especially with denosumab, and retreating with bisphosphonates if calcium does not normalize, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases and the American College of Physicians 4, 2, 6, 7, 8, 9
• The American Society of Clinical Oncology recommends avoiding pitfalls such as using diuretics before correcting hypovolemia, inadequate hydration before bisphosphonate administration, administering bisphosphonates too rapidly, treating laboratory values without addressing the underlying cause, delaying treatment of severe hypercalcemia, and failing to monitor for hypocalcemia after treatment, especially with denosumab 10